Improvement of brucellosis prevention : development of a vaccine and a serologic test using different recombinant antigens to discriminate vaccinated from infected animals

Informazioni relative al progetto

ID dell’accordo di sovvenzione: AGRE0049

Progetto chiuso

Data di avvio 1 Aprile 1991

Data di completamento 31 Marzo 1995

Finanziato da

• First multiannual programme (EEC) for biotechnology-based agro-industrial research and technological development (ECLAIR), 1988-1993

Costo totale

Nessun dato

Contributo UE

Nessun dato

Coordinato da

INNOGENETICS
Belgium

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Risultati sfruttabili

Brucellosis vaccine and serological test development

The aim of this research project has been the development of a new vaccine based on the knowledge of the pathogenesis of the Brucellosis bacteria and on the new technologies in the field of molecular genetics and immunology. Simultaneously, a diagnostic tool is being developed that will allow the differential diagnosis between animals treated with the new developed vaccine and infected animals.To achieve these goals Brucella protein antigens have been produced by recombinanat DNA techniques and their performance in serology has been evaluated. In parallel,presently available vaccine strains have been deleted in the genes encoding these diagnostic important proteins to avoid seroconversion upon vaccination. The strains have been studied in the mouse model to determine the residual virulence and to evaluate the protective effect upon challenge with a virulent Brucella strain. These experiments have yield encouraging results which warrent the furthur exploration of this vaccination and serology coupled system in a target animal like sheep or goats.